Catalyst Pharmaceuticals Reports Revenue Growth to $146.6 Million in Q2 2025

Catalyst Pharmaceuticals, Inc. reported significant financial growth in its latest 10-Q filing for the second quarter of 2025, with total revenues reaching approximately $146.6 million for the three months ended June 30, 2025, compared to $122.7 million for the same period in 2024. For the six months ended June 30, 2025, revenues totaled approximately $288.0 million, up from $221.2 million in the prior year. The increase in revenue was primarily driven by the successful commercialization of AGAMREE®, which contributed $27.4 million in net product revenue during the second quarter, compared to $8.7 million in the same quarter of the previous year. FIRDAPSE® also saw a revenue increase, generating $84.8 million in the second quarter, up from $77.4 million in 2024.

The company’s net income for the second quarter of 2025 was $52.1 million, or $0.43 per share, compared to $40.8 million, or $0.35 per share, in the same quarter of 2024. For the six-month period, net income was $108.8 million, or $0.89 per share, compared to $64.1 million, or $0.55 per share, in the prior year. This growth in profitability reflects a combination of increased product sales and effective cost management, with total operating costs rising to $80.3 million in the second quarter, up from $68.5 million in the same period last year.

Catalyst Pharmaceuticals has also made strategic advancements, including the acquisition of the U.S. rights to FYCOMPA® from Eisai in January 2023 and the exclusive North American license for AGAMREE® from Santhera in July 2023. The company launched AGAMREE® in the U.S. in March 2024, and it received FDA approval for the treatment of Duchenne muscular dystrophy (DMD) in October 2023. The company has since expanded its commercial team to support the marketing of both FIRDAPSE® and AGAMREE®, with a total of 59 field personnel dedicated to these products.

Operationally, Catalyst Pharmaceuticals reported a total of 122,391,010 shares of common stock outstanding as of August 4, 2025. The company has also maintained a strong cash position, with cash and cash equivalents totaling approximately $652.8 million at the end of the second quarter, up from $517.6 million at the end of 2024. This financial strength positions the company well for future growth and potential acquisitions, as it continues to explore opportunities to expand its product portfolio in the rare disease market.

Looking ahead, Catalyst Pharmaceuticals remains optimistic about its growth trajectory, particularly with the ongoing commercialization of its products and the potential for new product acquisitions. The company anticipates that its revenues will continue to fluctuate based on market conditions and the performance of its product lines, particularly as it faces the impending loss of exclusivity for FYCOMPA® in 2025. The company is committed to leveraging its financial resources to support its operations and strategic initiatives over the next 12 months and beyond.